What is the latest ZYDUSLIFE stock price?
The latest stored price for ZYDUSLIFE is Rs 1,160.00 as of 2026-09-18.
gimli
ZYDUSLIFE stock AI analysis
ZYDUSLIFE Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ZYDUS LIFESCIENCES LTD is a large-cap stock in Healthcare. This Gimli page shows the latest available ZYDUSLIFE price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,160.00
1W return
+3.78%
1M return
+3.98%
3M return
+7.97%
6M return
+28.95%
1Y return
+10.70%
Market cap
₹116,723.14 cr
PE
26.01
PB
3.95
ROE
+16.04%
ROCE
+9.12%
RSI
55.72
Turnover
₹323.55 cr
Why it can matter in screens
- Momentum: ZYDUSLIFE is above 50DMA, above 200DMA; RSI is 55.72.
- Returns: 1D +2.19%, 1W +3.78%, 1M +3.98%, 3M +7.97%, 1Y +10.70%.
- Trend levels: 52W high ₹1,205.00, 52W low ₹1,048.90, off high -3.73%.
- Liquidity: latest turnover is ₹323.55 cr; volume vs 20D is +2.09%.
- Valuation/profitability: PE 26.01, PB 3.95, ROE +16.04%, ROCE +9.12%.
- Growth: 3Y sales CAGR +16.54%, 3Y profit CAGR +36.98%.
Quick Answers
Is ZYDUSLIFE above its 50DMA and 200DMA?
ZYDUSLIFE is above 50DMA, above 200DMA. The latest 50DMA is 1,134.95 and the latest 200DMA is 1,000.38.
What are ZYDUSLIFE PE, ROE and ROCE?
ZYDUSLIFE has PE 26.01, ROE +16.04%, and ROCE +9.12% in Gimli's latest available snapshot.
How has ZYDUSLIFE performed recently?
ZYDUSLIFE has returned +3.98% over 1 month, +7.97% over 3 months, and +10.70% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 7,802.00 cr | 2,017.30 cr | 939.80 cr | nan |
| 2026-03-31 | 7,434.40 cr | 2,291.10 cr | 1,272.50 cr | 12.65 |
| 2025-12-31 | 6,780.40 cr | 1,842.90 cr | 1,042.10 cr | 10.36 |
| 2025-09-30 | 6,232.00 cr | 2,125.00 cr | 1,233.00 cr | 12.51 |
| 2025-06-30 | 6,467.00 cr | 2,243.40 cr | 1,466.80 cr | 14.58 |
| 2025-03-31 | 6,290.20 cr | 1,986.50 cr | 1,170.90 cr | 11.64 |
| 2024-12-31 | 5,123.50 cr | 1,445.10 cr | 1,023.50 cr | 10.17 |
| 2024-09-30 | 5,113.60 cr | 1,529.60 cr | n/a | nan |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 26,719.70 cr | 8,468.00 cr | 5,040.00 cr | 50.09 |
| 2025-03-31 | 22,573.80 cr | 7,108.40 cr | 4,525.50 cr | 44.97 |
| 2024-03-31 | 19,021.50 cr | 5,617.00 cr | 3,859.50 cr | 38.14 |
| 2023-03-31 | 16,877.80 cr | 3,437.90 cr | 1,960.30 cr | 19.30 |
| 2022-03-31 | 8,160.60 cr | 3,688.60 cr | 857.90 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 52,406.60 cr | 855.20 cr | 12,496.00 cr | 29,582.20 cr |
| 2025-03-31 | 37,201.70 cr | 826.80 cr | 3,213.20 cr | 26,358.40 cr |
| 2024-03-31 | 29,280.80 cr | 413.00 cr | 804.20 cr | 22,101.60 cr |
| 2023-03-31 | 25,756.40 cr | 487.80 cr | 1,194.90 cr | 19,688.30 cr |
| 2022-03-31 | 27,795.40 cr | 657.80 cr | 4,220.90 cr | 19,053.80 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 2,116.60 cr | -554.90 cr | n/a |
| 2025-03-31 | 6,781.10 cr | 5,087.40 cr | n/a |
| 2024-03-31 | 3,196.30 cr | 2,289.70 cr | n/a |
| 2023-03-31 | 2,688.80 cr | 1,657.90 cr | n/a |
| 2022-03-31 | 2,104.50 cr | 901.90 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +75.01% | +6.88% | +11.27% | +5.12% | +6.83% | +0.00% |
| 2026-06-18 | +75.01% | +6.89% | +11.19% | +4.92% | +6.90% | +0.00% |
| 2026-03-31 | +75.00% | +6.95% | +11.20% | +4.88% | +6.86% | +0.00% |
| 2025-12-31 | +75.00% | +7.06% | +11.09% | +4.71% | +6.85% | +0.00% |
| 2025-09-30 | +74.99% | +7.34% | +10.86% | +4.70% | +6.80% | +0.00% |
| 2025-06-30 | +74.99% | +7.13% | +11.13% | +5.56% | +6.74% | +0.00% |
| 2025-03-31 | +74.99% | +7.32% | +11.01% | +6.36% | +6.68% | +0.00% |
| 2024-12-31 | +74.98% | +7.53% | +10.65% | +6.32% | +6.84% | +0.00% |
| 2024-09-30 | +74.98% | +7.52% | +10.65% | +6.57% | +6.85% | +0.00% |
| 2024-06-30 | +74.98% | +5.59% | +12.64% | +7.24% | +6.80% | +0.00% |
| 2024-03-31 | +74.98% | +5.72% | +12.63% | +6.71% | +6.66% | +0.00% |
| 2023-12-31 | +74.98% | +5.00% | +13.03% | +6.99% | +6.99% | +0.00% |
| 2023-09-30 | +74.98% | +4.86% | +13.09% | +5.94% | +7.07% | +0.00% |
| 2023-06-30 | +74.98% | +4.04% | +13.52% | +5.80% | +7.47% | +0.00% |
| 2023-03-31 | +74.98% | +3.42% | +13.60% | +5.59% | +8.00% | +0.00% |
| 2022-12-31 | +74.98% | +2.52% | +13.69% | +5.56% | +8.81% | n/a |
| 2022-09-30 | +74.98% | +2.61% | +12.94% | +5.36% | +9.48% | n/a |
| 2022-06-30 | +74.88% | +0.08% | +14.80% | n/a | n/a | +0.00% |
| 2022-03-31 | +74.88% | +0.08% | +15.36% | n/a | n/a | +0.00% |
| 2021-12-31 | +74.88% | +0.07% | +15.59% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
| AUROPHARMA | AUROBINDO PHARMA LTD | 99,770.53 cr | 29.199136 | +9.69% | +53.60% |
Try these prompts
- Analyze ZYDUS LIFESCIENCES with valuation, momentum and industry peers
- Compare ZYDUSLIFE with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare ZYDUSLIFE with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.